Angina Pectoris Drugs Market Share, Growth & Forecast [2030]

Segments - Angina Pectoris Drugs Market by Therapeutic Classes (Anti-Platelets, Calcium Antagonists, Anticoagulants, Beta Blockers, and Others [Nitrates, Anti-anginal, and ACE inhibitors]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global angina pectoris drugs market size is expected to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased expenditure in healthcare, availability of drugs treatment, and rising number of targeted population.

Angina Pectoris Drugs Market key takeaways

Angina pectoris drugs are used to treat the angina pectoris condition, which is normally occurred due to reduced blood flow to the heart muscle. Some key symptoms of this condition include pain in the body especially discomfort in chest, back, neck, and shoulders. This health condition is expected to occur due to angioplasty, drugs, artery bypass surgery, and lifestyle changes while it can be categorized as microvascular, prinzmetal, stable, and unstable variant. It majorly impact on quality of life, ability to work, and costs to the society.

Prevalence of chronic stable angina pectoris is expected to be 2-4% in the seven key markets namely Japan, Germany, the U.S., Italy, Spain, the U.K., and France. Over 8 million men and women in the U.S. are suffering from chronic angina pectoris, as per a latest report by Heart Disease and Stroke Statistics from the American Heart Association. The incidences of angina increases in both genders with age, ranging from 2-4% in men aged 65-74 and 0.1-1% in women aged 45-54.

Market Trends, Drivers, Restraints, and Opportunities

Increasing demand for targeted treatments, available effective treatment method, and increased expenditure on healthcare globally are expected to drive the market growth.
Increasing geriatric population in countries such as developed countries such as the US and the UK are expected to influence the demand for angina pectoris drugs in the coming years.
Favorable government policies across the globe for adoption and approval of clinical trials of advanced therapy medicinal products are expected to boost the market.
Continuously expansion in the activities such as investments for innovative products and collaborations is expected to fuel the market growth.
Declining of branded sales of the drugs due to condition of a larger portion of prescriptions is a key challenge expected to restrain the market growth.

Scope of the Report

The report on the global angina pectoris drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Angina Pectoris Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Therapeutic Classes (Anti-Platelets, Calcium Antagonists, Anticoagulants, Beta Blockers, and Others [Nitrates, Anti-anginal, and ACE inhibitors])
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	SANOFI-Synthelabo (India) Private Limited.; Gilead Sciences, Inc.; Amgen, Inc.; GlaxoSmithKline Plc.; AstraZeneca Plc.; Eli Lilly and Company; Pfizer, Inc.; Novartis International AG; XyloCor Therapeutics, Inc.; and Tasly Pharmaceuticals, Inc.

Market Segment Insights

Beta blockers segment is expected to grow at a rapid pace

Based on therapeutic classes, the global angina pectoris drugs market is divided into anti-platelets, calcium antagonists, anticoagulants, beta blockers, and others. The other segment is further divided into nitrates, anti-anginal, and ace inhibitors. The beta blockers segment is expected to grow at a rapid pace in the coming years owing to rising adoption of therapeutic methods among the patients of angina pectoris. However, the others segment is attributed to account for a key market share during the forecast period due to advancement in technology and various research and development initiatives by several governments.

Angina Pectoris Drugs Market by Therapautic Classes

North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to the presence of major market players and rising adoption of therapeutics in the region. Meanwhile, the market of Asia Pacific is projected to exhibit a substantial growth rate during the forecast period due to the large population and unmet medical needs in the region.

Segments

Segments Covered in the Report
The global angina pectoris drugs market has been segmented on the basis of

Therapeutic Classes

Anti-Platelets
Calcium Antagonists
Anticoagulants
Beta Blockers
Others
- Nitrates
- Anti-anginal
- ACE inhibitors

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

SANOFI-Synthelabo (India) Private Limited
Gilead Sciences, Inc.
Amgen, Inc.
GlaxoSmithKline Plc.
AstraZeneca Plc.
Eli Lilly and Company
Pfizer, Inc.
Novartis International AG
XyloCor Therapeutics, Inc.
Tasly Pharmaceuticals, Inc.

Competitive Landscape

Key players competing in the global angina pectoris drugs market are SANOFI-Synthelabo (India) Private Limited.; Gilead Sciences, Inc.; Amgen, Inc.; GlaxoSmithKline Plc.; AstraZeneca Plc.; Eli Lilly and Company; Pfizer, Inc.; Novartis International AG; XyloCor Therapeutics, Inc.; and Tasly Pharmaceuticals, Inc.

The main market players are continuously engaged in the activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to strengthen their products portfolio and consumer base.

Angina Pectoris Drugs Market by key players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Angina Pectoris Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Angina Pectoris Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Angina Pectoris Drugs Market - Supply Chain
  4.5. Global Angina Pectoris Drugs Market Forecast
     4.5.1. Angina Pectoris Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Angina Pectoris Drugs Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Angina Pectoris Drugs Market Absolute $ Opportunity
5. Global Angina Pectoris Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Angina Pectoris Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Angina Pectoris Drugs Demand Share Forecast, 2019-2026
6. North America Angina Pectoris Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Angina Pectoris Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Angina Pectoris Drugs Demand Share Forecast, 2019-2026
7. Latin America Angina Pectoris Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Angina Pectoris Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Angina Pectoris Drugs Demand Share Forecast, 2019-2026
8. Europe Angina Pectoris Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Angina Pectoris Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Angina Pectoris Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Angina Pectoris Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Angina Pectoris Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Angina Pectoris Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Angina Pectoris Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Angina Pectoris Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Angina Pectoris Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Angina Pectoris Drugs Market: Market Share Analysis
  11.2. Angina Pectoris Drugs Distributors and Customers
  11.3. Angina Pectoris Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. SANOFI-Synthelabo (India) Private Limited
     11.4.2. Gilead Sciences, Inc.
     11.4.3. Amgen, Inc.
     11.4.4. GlaxoSmithKline Plc.
     11.4.5. AstraZeneca Plc.
     11.4.6. Eli Lilly and Company
     11.4.7. Pfizer, Inc.
     11.4.8.